| For: |
Fakheri H, Bari Z, Aarabi M, Malekzadeh R. |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i30/10355.htm |
| Number | Citing Articles |
| 1 |
Muhammad Miftahussurur, Yoshio Yamaoka. Appropriate First-Line Regimens to Combat Helicobacter pylori Antibiotic Resistance: An Asian Perspective. Molecules 2015; 20(4) doi: 10.3390/molecules20046068
|
| 2 |
L. M. Lawson-Ananissoh, O. Bouglouga, A. Bagny, R. El-Hadj Yakoubou, L. Kaaga, D. Redah. Profil épidémiologique des ulcères gastro-duodénaux au centre hospitalier et universitaire Campus de Lomé (Togo). Journal Africain d'Hépato-Gastroentérologie 2015; 9(3) doi: 10.1007/s12157-015-0597-5
|
| 3 |
Bahareh Attaran, Tahereh Falsafi, Nassim Ghorbanmehr. Effect of biofilm formation by clinical isolates of <i>Helicobacter pylori</i> on the efflux-mediated resistance to commonly used antibiotics. World Journal of Gastroenterology 2017; 23(7): 1163-1170 doi: 10.3748/wjg.v23.i7.1163
|
| 4 |
Samin Alihosseini, Reza Ghotaslou, Fatemah Sadeghpour Heravi, Zainab Ahmadian, Hamed Ebrahimzadeh Leylabadlo. Management of antibiotic-resistantHelicobacter pyloriinfection: current perspective in Iran. Journal of Chemotherapy 2020; 32(6) doi: 10.1080/1120009X.2020.1790889
|
| 5 |
Muhammad Miftahussurur, Yoshio Yamaoka. Helicobacter pylori Research. 2016; doi: 10.1007/978-4-431-55936-8_23
|
| 6 |
Akihiko Komuro. Japanese Kampo Medicines for the Treatment of Common Diseases: Focus on Inflammation. 2017; doi: 10.1016/B978-0-12-809398-6.00014-7
|
| 7 |
Ya-Wen Zhang, Wei-Ling Hu, Yuan Cai, Wen-Fang Zheng, Qin Du, John J Kim, John Y Kao, Ning Dai, Jian-Min Si. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for <i>Helicobacter pylori</i> infection and predictors of failed eradication. World Journal of Gastroenterology 2018; 24(40): 4596-4605 doi: 10.3748/wjg.v24.i40.4596
|
| 8 |
Marjan Mohammadi, Bahareh Attaran, Reza Malekzadeh, David Y. Graham. Furazolidone, an Underutilized Drug for H. pylori Eradication: Lessons from Iran. Digestive Diseases and Sciences 2017; 62(8) doi: 10.1007/s10620-017-4628-5
|
| 9 |
Alireza Bakhshipour, Narges Mohsenpour Mohammadi, Seyed Mahdi Hashemi, Mohammad Kazem Momeni. Comparison of Clarithromycin-based Triple Therapy and Furazolidone-based Quadruple Therapy in Eradicating Helicobacter pylori Infection. International Journal of Infection 2021; 8(1) doi: 10.5812/iji.98954
|
| 10 |
Hamid Abdollahi, Mohammad Hashemzadeh, Saeed Khoshnood, Mohammad Savari. Characterization of Helicobacter pylori genotypes from Iranian patients with gastric clinical diseases: Predominance of vacA s1a and cagA EPIYA-ABC genotypes. Gene Reports 2019; 16 doi: 10.1016/j.genrep.2019.100458
|
| 11 |
Atieh Makhlough, Hafez Fakheri, Samaneh Hojati, Vahid Hosseini, Zohreh Bari. A Comparison between Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Eradication in Patients with Uremia: A Randomized Clinical Trial. Middle East Journal of Digestive Diseases 2015; 8(1) doi: 10.15171/mejdd.2016.05
|
| 12 |
Leila Lormohammadi, Farhad Nikkhahi, Shahin Bolori, Ali Akbar Karami, Sepideh Hajian, Neda Rad, Amir Peymani, Rasoul Samimi. High level of resistance to metronidazole and clarithromycin among Helicobacter pylori clinical isolates in Qazvin province, Iran. Gene Reports 2022; 26 doi: 10.1016/j.genrep.2022.101494
|
| 13 |
Reza Khashei, Mahintaj Dara, Abdollah Bazargani, Kamran Bagheri Lankarani, Alireza Taghavi, Maryam Moeini, Behzad Dehghani, Maryam Sohrabi. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. APMIS 2016; 124(9) doi: 10.1111/apm.12567
|
| 14 |
Laleh Mahmoudi, Shohreh Farshad, Mehrdad Seddigh, Paria Mahmoudi, Fardad Ejtehadi, Ramin Niknam. High efficacy of gemifloxacin-containing therapy in Helicobacter Pylori eradication. Medicine 2016; 95(42) doi: 10.1097/MD.0000000000004410
|
| 15 |
Su Young Kim, Duck Joo Choi, Jun-Won Chung. Antibiotic treatment for <italic>Helicobacter pylori</italic>: Is the end coming?. World Journal of Gastrointestinal Pharmacology and Therapeutics 2015; 6(4): 183-198 doi: 10.4292/wjgpt.v6.i4.183
|
| 16 |
Hafez Fakheri, Mehdi Saberi Firoozi, Zohreh Bari. Eradication of Helicobacter Pylori in Iran: A Review. Middle East Journal of Digestive Diseases 2017; 10(1) doi: 10.15171/mejdd.2017.84
|
| 17 |
Hassan Salmanroghani, Massoud Mirvakili, Mahmud Baghbanian, Roham Salmanroghani, Golshid Sanati, Pouria Yazdian, John Green. Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PLOS ONE 2018; 13(6) doi: 10.1371/journal.pone.0197096
|
| 18 |
Mitra Mahmoudi Meymand, Fatemeh Salajegheh, Farhad Sarafzadeh, Mahmoud Reza Heidari, Fatemeh Dabaghzadeh. Exploring the Link Between Dietary Micronutrient Intake and <i>Helicobacter pylori</i> Positivity: A Case-Control Study. Jundishapur Journal of Natural Pharmaceutical Products 2026; 21(4) doi: 10.5812/jjnpp-172796
|
| 19 |
Leila Manzouri, Farzaneh Zarei, Narjes Niazi, Moslem Sedaghattalab. Comparison of the Success Rate of Quadruple and Triple Antibiotic Therapy in Eradicating Helicobacter pylori Infection in Southwest of Iran: A Randomized Clinical Trial. International Journal of Infection 2017; 4(3) doi: 10.5812/iji.15610
|
| 20 |
Parisa Abedi Elkhichi, Masoumeh Aslanimehr, Adeleh Atar. A SYSTEMATIC REVIEW OF THE TREATMENT OF HELICOBACTER PYLORI BY THE EFFECT OF PROBIOTICS IN ASIAN POPULATION. Studies in Medical Sciences 2023; 34(3) doi: 10.61186/umj.34.3.116
|